The biotech company BridgeBio announced on Monday that a medicine it created to treat a cardiac ailment that is becoming more common achieved its primary objective in a clinical trial and also decreased the chance of mortality by 25% when compared to a placebo.
The outcomes could pave the way for the drug acoramidis to reach the market following a failure that caused its manufacturer’s stock to crash in December 2021.
Since the initial failure, a competing Pfizer drug has established itself even further, while an Alnylam Pharmaceuticals drug has experienced a positive clinical outcome in the heart illness known as ATTR-CM, in which a faulty protein causes clumps to accumulate in the heart.
